Pancryos strikes deal with Brigham and Women’s Hospital on type 1 diabetes drug
The Copenhagen-based firm has entered a global license agreement with Brigham and Women’s Hospital regarding an encapsulation device for the delivery of a stem-cell derived treatment for type 1 diabetes.
by christopher due karlsson, translated by daniel pedersen
Pancryos, which is based out of Copenhagen, Denmark, is working on a stem-cell based treatment for type 1 diabetes dubbed Paninsula, and has now signed an exclusive license deal with the US-based Brigham and Women’s Hospital (BWH), the firm reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Dexcom is in talks to acquire device firm Insulet
For subscribers
Novo Nordisk regains Novorapid supply capacity
For subscribers
FDA approves Eli Lilly diabetes drug
For subscribers
